News & Events
Cobalis Corporation is Awarded Two New International Patents in Canada and Mexico for its Revolutionary Anti-Allergy Relief Product PreHistin®
IRVNE, CA--Cobalis Corporation (OTC: CLSC) was recently awarded two additional International Patents in Canada and Mexico and has a patent pending application in Japan. PreHistin® is patented, safe for long-term daily use and available without a prescription. It is available in a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers’ response to both indoor and outdoor allergens with daily and year round usage.
Cobalis representatives indicate, “Cyanocobalamin has an excellent safety record, has been safety accepted by the US FDA, and has no upper dosage limits or contra-drug indications. For over 50 years the FDA has approved cyanocobalamin as a drug for anemia. Each PreHistin® lozenge contains 3.3mg Cyanocobalamin. For less than $1.00 per day, twice daily use of PreHistin® has been clinically shown to significantly increase serum vitamin B12 levels, making PreHistin® a cost effective and convenient alternative to other Vitamin B12 therapies, including needle injections.
Cobalis Board Member, Dr. Kevin Prendiville states, “These new patents, in addition to the European Union, Australian and two U.S patents further strengthen the value and assets of Cobalis Corporation intellectual properties. Furthermore, PreHistin®’s box, labeling and related box insert have been approved by DSHEA (Dietary Supplement Health and Education Act) regulation attorneys.”
ABOUT COBALIS CORP—PREHISTIN(® “The World’s First Pre-Histamine”
Headquartered in Irvine, California, Cobalis Corp. is an over the counter pharmaceutical and nutraceutical company. Its flagship product, PreHistin® is designed to prevent the primary causes of airborne allergies. PreHistin®, “The World’s First Pre-Histamine” is the only Phase III clinically tested sublingual product fully patented for long term and daily use without a prescription to help relieve allergy sufferers of both indoor and outdoor allergens.
PreHistin(R)® is manufactured by Monarch Nutraceutical Inc., a division of Nutraceutical Corporation in Ogden Utah. Nutraceutical Corp. ( NUTR) was the original manufacturer of PreHistin(R)® under the name Alleratin, which was distributed to thousands of allergy suffers without cost for compassionate use. Additional PreHistin(R) manufacturing partners include Marrs Printing, Walnut, CA and Merical Inc, Anaheim, CA. Domestic and international PreHistin® orders are currently fulfilled by International Sales and Marketing (ISM), Newark, NJ.
For product information and ordering please visit at www.PreHistin.com or call toll free
1-877-4POLLEN. For additional company information please visit their website at www.Cobalis.com
###
Cobalis Announces New Toll Free Order Number 1-877-4POLLEN and All Major Credit Card Merchant Processing for PreHistin® Allergy Relief Sales at www. PreHistin.com
IRVINE, CA--Cobalis Corporation (OTC-Clsc) is pleased to announce that effective immediately all major credit cards are now accepted for PreHistin® orders at www.PreHistin.com in addition to the already accepted PayPal method. PreHistin®, “The World’s First Pre-Histamine” may also be ordered directly by calling toll free 1-877-4POLLEN.
Cobalis also announces that effective immediately they have moved their corporate offices to:
2030 Main St.
Suite 1300
Irvine CA 92614
949-260-9007
Relocation back to Irvine, CA, the original Southern California municipal corporate headquarter location for Cobalis marks a significant turning point in the companies transition to a commercial organization focused on the manufacture, marketing, international distribution and sales of PreHistin® for allergy sufferers world wide.
Cobalis is committed to their international branding campaign for PreHistin® as “the choice for all natural allergy relief”, as the company capitalizes on their extensive and growing international patent portfolio, including two U.S Patents #5,135,918 “Method for Decreasing Reaginic Antibody Levels” and #6,255,294 “Cyanocobalamin Treatment in Allergic Disease”.
ABOUT COBALIS CORP—PREHISTIN®
Cobalis Corp. is an over the counter pharmaceutical and nutraceutical company. Its flagship product, PreHistin® is designed to prevent the primary causes of airborne allergies.
PreHistin®, “The World’s First Pre-Histamine” is the only Phase III clinically tested sublingual product fully patented for long term and daily use without a prescription to help relieve allergy sufferers from both indoor and outdoor allergens.
PreHistin® has shown in previous clinical studies to modulate the body’s level of immunoglobulin E (IgE), thus reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Studies have shown that the active ingredient in PreHistin®, an FDA safety approved 3.3 mg Cyanocobalamin (Vitamin B12) mega-dose sub-lingual lozenge has essentially no risks or adverse side effects to the general population including sedation and drowsiness found in many allergy medications currently available.
For product information and ordering please visit at www.PreHistin.com or call toll free
1-877-4POLLEN. For additional company information please visit their website at www.Cobalis.com
Contact:
Cobalis Corporation
info@cobalis.com
949-260-9007
or
Investor Relations
Investsource
Roy Sahachaisere
714-847-2460
###
Cobalis Corporation and International Shipping and Marketing LLC announce signed Letter of Intent for Distribution and Marketing of Flagship Anti-Allergy Product PreHistin(R)
IRVINE, Calif.—(BUSINESS WIRE)-- Cobalis Corporation (OTC: CLSC-NEWS), a pharmaceutical and nutraceutical biotechnology company specializing in the development of anti-allergy medications announced today that they have completed a signed Letter of Intent (LOI) with International Shipping and Marketing LLC (ISM) to distribute and market PreHistin(R). PreHistin(R) is Cobalis’ patented revolutionary allergy prevention product available for worldwide sales at www.PreHistin.com.
ISM, located in Newark, New Jersey will immediately begin order fulfillment for Cobalis’ PreHistin(R) domestic and international sales while also agreeing to begin wholesale distribution and marketing for PreHistin(R) sales in the Eastern United States. The agreement with ISM also grants approval for them as an affiliate marketer for PreHistin(R) internet sales at www.PreHistin.com.
Effective May 11, 2009 ISM placed $100,000.00 into an escrow account to purchase and market PreHistin(R) for distribution. Michael Scalora, a managing partner for ISM states, “We are proud to introduce PreHistin(R) to the Eastern United States and will begin fulfilling PreHistin(R) orders for Cobalis Corporation immediately from our existing international shipping and distribution center in the Garden State”.
Mr. Scalora further commented, “Although we are extremely excited to immediately implement our $500,000 annual marketing budget for the PreHistin(R) branding and awareness campaign for the Eastern United States, we are working very closely and in partnership with Cobalis to ensure that we seek and receive all necessary court approvals. We are very pleased to partner with Cobalis to market PreHistin(R) as the “The World’s First Pre-Histamine” and the preemminent international brand for all natural allergy relief. We have not found a competitive product, backed by research and clinical trials that remotely compares to PreHistin(R) as a safe, non-drowsy and side effect free alternative to typical prescription allergy medications that are intended to treat the symptoms after histamine has already been released. As the PreHistin(R) slogan states, “Stop allergies before they start”.”
Cobalis Corporation, currently in Chapter 11 bankruptcy protection, is responding to pending Court motions and is scheduled for a court hearing on June 10, 2009. At that time, Cobalis will present evidence in an attempt to support continuation in Chapter 11 as opposed to having the case convert to Chapter 7, which could result in liquidation of their assets including patents and intellectual property. In addition, Cobalis will propose commencement of efforts to effect a work-out plan in 2009 to emerge from Chapter 11. While in Chapter 11, Cobalis may continue to operate and monetize their significant international and domestic patents for PreHistin®.
ABOUT COBALIS CORP—PREHISTIN(R)®
Headquartered in Irvine, California, Cobalis Corp. is an over the counter pharmaceutical and nutraceutical company. Its flagship product, PreHistin(R) ® is designed to prevent the primary causes of airborne allergies.
PreHistin(R), “The World’s First Pre-Histamine” is the only Phase III clinically tested sublingual product fully patented for long term and daily use without a prescription to help relieve allergy sufferers of indoor and outdoor airborne allergen.
PreHistin(R) has shown in previous studies to modulate the body’s level of immunoglobulin E (IgE), thus reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin(R) has essentially no risks or adverse effects to the general population including sedation and drowsiness found in most of the allergy products now available.
Cobalis welcomes your ideas and resources and is actively seeking companies and individuals to support Cobalis’efforts to launch PreHistin(R) globally.
For additional company information please visit their website at www.Cobalis.com. For product information and ordering please visit at www.PreHistin.com.
.
ABOUT INTERNATIONAL SHIPPING AND MARKETING LLC
Headquartered in Newark, New Jersey, ISM LLC is located and managed within the current 11,000 sq foot headquarters of the managing partner’s existing and well funded 20 year old international shipping and distribution company. ISM’s two managing partners and their established finance, operations and marketing team have well over 50 years of successful and profitable management experience in international shipping and distribution, internet marketing, and financial and business management. ISM and their facilities and employees are in place and prepared to manage worldwide fulfillment and Eastern US sales, marketing and distribution of PreHistin(R) for Cobalis Corporation. ISM is committed to employing any additional resources required to make the PreHistin(R) brand a success.
Contact:
Cobalis Corporation
info@cobalis.com
or
INvenstor Relaions Contact:
Roy Sahachaisere
714-847-2460
###
Cobalis Corp (CLSC) Launches Patented Revolutionary Allergy Prevention Product PreHistin® for World Wide Sales at www.PreHistin.com.
LAGUNA BEACH, Calif. – May 8, 2009 – Cobalis Corp. (CLSC.PK), a pharmaceutical biotech company specializing in the development of anti-allergy medications announced today that their patented revolutionary allergy prevention product PreHistin® is now available for worldwide commercial sales and orders at www.prehistin.com.
During multiple clinical trials conducted by Cobalis Corp, pre-seasonal treatment with PreHistin® was shown to reduce and regulate IgE levels and their resultant histamine production in both allergy and non-allergy sufferers. Cobalis Corp. has conducted numerous clinical trials in over 30 board certified clinics throughout the U.S.with over 2200 patients in the Phase III trials of PreHistin®. As a result, the data from the clinical trials enables Cobalis to launch patented PreHistin® as a nutraceutical supplement with clinical claims.
Dr. Paul Ratner, the lead clinical investigator during Cobalis trials of Prehistin® and a Board Certified Allergist, as well as a Fellow of the American Academy of Allergy and Immunology, said, “Results were dramatic. PreHistin® was safe, showed no side effects and was non-drowsy. Prehistin® is a novel therapy that can be taken preventatively and works extremely well.”
PreHistin® is being manufactured by Monarch Nutraceutical, a division of Nutraceutical Corp in Ogden, Utah. Nutraceutical Corp. (NUTR) was the original manufacturer of PreHistin® under the name Alleratin, which was distributed to thousands of allergy suffers without cost for compassionate use.
Chas Radovich, the President of Cobalis, stated, “We are extremely proud to have reached this milestone turning Cobalis from a research corporation to a commercially viable company with the launch of Prehistin® for immediate domestic and international sales to the public at www.prehistin.com. World wide fulfillment of customer orders for our initial internet marketing campaign for PreHistin will commence next week. Prehistin® is a patented product, safe for long-term daily use and available without a prescription. Prehistin® is a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers response to both indoor and outdoor allergens with daily and year round usage.”
Cyanocobalamin has an excellent safety record, is safety accepted by the US FDA, and has no upper dosage limits or contra-drug indications. For over 50 years the FDA has approved cyanocobalamin as a drug for anemia. Each Prehistin® lozenge contains 3.3mg Cyanocobalamin. For less than $1.00 per day, twice daily use of PreHistin has been clinically shown to significantly increase serum vitamin B12 levels, making PreHistin® a cost effective and convenient alternative to other Vitamin B12 therapies.
Mr. Radovich continued, “After many years of research, we are finally able to make
PreHistin® available to the over 55,000,000 allergy sufferers in the United States, many of whom have been waiting for an all natural and preventive alternative to their allergy problems. Immediate commencement of sales through www.PreHistin.com marks the beginning of our domestic and international distribution sales partnerships and channels for PreHistin®.”
ABOUT COBALIS CORP—PREHISTIN®
Headquarter in Laguna Beach, California, Cobalis Corp. is an over the counter pharmaceutical company. Its flagship product, PreHistin® is designed to prevent the primary causes of airborne allergies. The anti allergy market is projected to be over fifteen billion dollars by 2010, and PreHistin® is in the unique position of being the only Phase III clinically tested sublingual product with outstanding test results and is poised to get its share of the market.
PreHistin, “the world’s first pre-histamine,” has shown in previous studies to modulate the body’s level of protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin has essentially no risks or adverse effects to the general population including sedation drowsiness found in most of the allergy products now available.
For company info please visit our website at www.Cobalis.com. For product info and ordering please visit at www.prehistin.com.
###
Cobalis Corp enters into a Master Broker Agreement with MDC
to help launch PreHistin® into global markets.
Laguna Beach, Calif. – January 21, 2009 - Cobalis Corp. (CLSC.PK), a pharmaceutical biotech company specializing in the development of anti-allergy medications, announced today that they have entered into a Master Broker agreement with Melodic Distribution Company (MDC). The goal of the agreement is to take advantage of MDC’s strong international distribution channels and strategic partners.
MDC will seek international distribution for PreHistin™ within its vast network throughout Europe, Australia and Asia. MDC has received very strong indications of interest from its key distribution partners and will look to secure multiple distribution agreements in the near term.
Key members of MDC have worked previously with Cobalis to secure and manage the manufacturing of PreHistin for both FDA Phase III trials. The MDC team has extensive experience in manufacturing, distribution, marketing and branding of OTC nutritional supplements.
Steven Barnes, a managing partner of MDC and co-head of international distribution, said, “We are very pleased and excited to be a part of the international launch of PreHistin. We have been well aware of PreHistin’s potential and efficacy through all of the anecdotal evidence we received from friends and family that have sampled the product over the years. This is a very unique product that completely differentiates itself from the current list of anti-histamines that dominate the marketplace.”
Chas Radovich, the CEO of Cobalis, said, “We are very excited to have MDC represent us in the international distribution community. They are extremely well connected in all territories that Cobalis plans to penetrate. This will expedite our ability to launch PreHistin overseas and will coincide with our initial launch first quarter 2009 in the United States.”
ABOUT COBALIS CORP--PREHISTIN™
Headquartered in Laguna Beach, California, Cobalis Corp. is an over-the-counter pharmaceutical company. Its flagship product PreHistin™ is designed to prevent the primary causes of airborne allergies, and is set for launch first quarter 2009. The anti-allergy market is projected to exceed $10 Billion annually by 2010, and PreHistin™ is poised to capture significant market share. PreHistin™ is singularly positioned as it is the only Phase III clinically tested sublingual anti-allergy product with demonstrated efficacy.
PreHistin™, the “world’s first pre-histamine,” has shown in previous studies to modulate the body’s level of protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin™ has essentially no risks or adverse effects to the general population including sedation and drowsiness found in most of the allergy products now available.
For more info please visit our website at www.Cobalis.com.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
###
Cobalis Corp Gets Federal Court Approval to Launch Its Flagship Anti Allergy Product PreHistin®
LAGUNA BEACH, CA – January 15, 2009 – Cobalis Corp. (OTC: CLSC), a pharmaceutical biotech Company specializing in the development of anti allergy medications, today announced the planned marketing launch of the flagship anti-allergy product PreHistin™ after approval in Federal Court in Santa Ana, CA on Jan.13, 2009. The launch of PreHistin™ is scheduled for February 2009, and will enable the company to be discharged from Chapter 11.
Cobalis Corp. has conducted numerous clinical trials in over 30 board certified clinics with physicians throughout the U.S. with over 2200 patients in the Phase III trials of PreHistin™. The Company has demonstrated that pre seasonal treatment with PreHistin™ was seen to clearly reduce allergy symptoms without causing any side effects. The data from the clinical trials will enable Cobalis to launch PreHistin ™ as a nutraceutical with clinical claims.
Cobalis Corp. has a manufacturing agreement with Monarch Nutraceuticals, a division of Nutraceutical Corp. (Nasdaq: NUTR) in Ogden, Utah, to manufacture and produce PreHistin™. Nutraceutical Corp. is the original manufacturer of PreHistin™ under the name Alleratin, which was distributed to thousands of allergy sufferers at no charge for compassionate use.
Chas Radovich, the CEO of Cobalis, said, “We are extremely proud to have reached the milestone of being able to launch PreHistin™, our flagship product in February 2009. The product will be available to the general public and to over 10,000 previous PreHistin™ users from the Phase III trials and allergy suffers who received compassionate use product over the years.” Mr. Radovich went on to say, “We will finally be able to get our products to the over 50,000,000 allergy sufferers in the United States who have been waiting for a natural alternative to treat or prevent allergies.”
ABOUT COBALIS CORP--PREHISTIN™
Headquarter in Laguna Beach, California, Cobalis Corp. is an over-the-counter pharmaceutical company. Its flagship product PreHistin™ is designed to prevent the primary causes of airborne allergies, and is set for launch in February 2009.
The anti allergy market is projected to exceed $10 Billion annually by 2010, and PreHistin™ is poised to capture significant market share. PreHistin™ is singularly positioned as it is the only Phase III clinically tested sublingual anti-allergy product with demonstrated efficacy.
PreHistin™, the “world’s first pre-histamine,” has shown in previous studies to modulate the body’s level of protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin™ has essentially no risks or adverse effects to the general population including sedation and drowsiness found in most of the allergy products now available.
For more info please visit our website at www.Cobalis.com.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
###
